Table 1.

Baseline characteristics of the included RCTs in the meta-analysis

Author, year	Therapeutic schedule	Average age (years)	Male	Duration of PsA, years	PASI score (0–72)	Swollen joint count (0–66)	Tender joint count (0–68)
Deodhar, Atul 2018	Guselkumab 100 mg at week 0, week 4, and every 8 weeks	47	52%	7.0 ± 7.2	12.0 ± 10.5	11.9 ± 7.6	20.7 ± 12.2
	Placebo	44	24%	6.9 ± 7.2	9.9 ± 8.0	10.6 ± 7.5	20.1 ± 12.5
Mease, Philip J. 2020	Guselkumab 100 mg every 4 weeks	46	58%	5.5 ± 5.9	10.8 ± 11.7	12.9 ± 7.8	22.4 ± 13.5
	Guselkumab 100 mg at weeks 0, 4, then every 8 weeks	45	52%	5.1 ± 5.5	9.7 ± 11.7	11.7 ± 6.8	19.8 ± 11.9
	Placebo	46	48%	5.8 ± 5.6	9.3 ± 9.8	12.3 ± 6.9	21.6 ± 13.1
Coates, L. C. 2022	Guselkumab 100 mg week 0, week 4, then every 8 weeks	49	46%	8.3 ± 7.8	11.7 ± 11.9	10.0 ± 7.0	21.0 ± 13.0
	Placebo	49	54%	8.7 ± 7.2	9.2 ± 9.4	9.0 ± 6.0	18.0 ± 11.0
Kristensen, L. E. 2022	Risankizumab 150mg at weeks 0, 4 and 16	52	52%	7.1 ± 7.0	10.9 ± 10.1	12.1 ± 7.8	20.8 ± 14.1
	Placebo	52	49%	7.1 ± 7.7	10.0 ± 10.4	12.2 ± 8.0	20.5 ± 12.8
Ostor, A. 2022	Risankizumab 150mg at weeks 0, 4 and 16	53	45%	8.2 ± 8.2	7.7 ± 6.7	13.0 ± 8.7	22.8 ± 14.9
	Placebo	52	45%	8.2 ± 8.3	8.4 ± 9.9	13.6 ± 9.0	22.3 ± 13.8
Philip J Mease 2021	Tildrakizumab 200 mg every 4 weeks	50	41%	7.5 ± 8.5	7.6 ± 9.8	10.4 ± 7.4	16.6 ± 11.9
	Tildrakizumab 200 mg every 12 weeks	49	53%	6.2 ± 7.2	6.2 ± 7.4	10.0 ± 8.0	19.5 ± 13.9
	Tildrakizumab 100 mg every 12 weeks	49	39%	7.0 ± 6.6	8.8 ± 9.5	11.0 ± 8.2	21.3 ± 14.8
	Tildrakizumab 20 mg every 12 weeks	47	47%	6.6 ± 6.7	5.5 ± 2.1	9.4 ± 6.4	19.0 ± 13.0
	Placebo	48	44%	6.3 ± 6.1	5.0 ± 6.5	11.8 ± 9.8	19.7 ± 14.7

RCT, randomized controlled trial; PsA, psoriatic arthritis; PASI, Psoriasis Area Severity Index